1. Home
  2. PFSI vs DNTH Comparison

PFSI vs DNTH Comparison

Compare PFSI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PFSI

PennyMac Financial Services Inc.

HOLD

Current Price

$92.17

Market Cap

4.7B

Sector

Finance

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$87.71

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFSI
DNTH
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.6B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
PFSI
DNTH
Price
$92.17
$87.71
Analyst Decision
Buy
Strong Buy
Analyst Count
9
13
Target Price
$128.11
$121.00
AVG Volume (30 Days)
438.1K
540.5K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
1.35%
N/A
EPS Growth
59.25
N/A
EPS
9.30
N/A
Revenue
$984,629,000.00
$2,036,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$16.96
$29.48
P/E Ratio
$9.71
N/A
Revenue Growth
3.05
N/A
52 Week Low
$82.65
$16.77
52 Week High
$160.36
$96.50

Technical Indicators

Market Signals
Indicator
PFSI
DNTH
Relative Strength Index (RSI) 53.94 54.40
Support Level $91.78 $33.94
Resistance Level $95.79 $88.45
Average True Range (ATR) 2.15 3.93
MACD 0.03 -1.43
Stochastic Oscillator 50.21 38.75

Price Performance

Historical Comparison
PFSI
DNTH

About PFSI PennyMac Financial Services Inc.

PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: